| Document |
Document Title |
|
WO/2022/071591A1 |
The present invention provides a new medical agent that inhibits aggregation of amyloid-β causing Alzheimer's disease and the like. The amyloid-β aggregation inhibitor according to the present invention is characterized by including ...
|
|
WO/2022/071574A1 |
Provided is a carbonated aerosol for topical use comprising an aerosol stock solution containing components (A) through (D), and a propellant containing component (E). (A) A ceramide lipid (B) An ionic surfactant (C) A water-soluble po...
|
|
WO/2022/071580A1 |
In the present invention, a low-molecular-weight compound 2,2,6,6-tetramtethyl-1-piperidinyloxyl (TEMPO) in the gas state is allowed to act on cells to suppress cell death associated with oxidative stress, thereby protecting tissue from ...
|
|
WO/2022/071879A1 |
Calcium supplements in the form of a salt substitute, including sodium chloride; potassium chloride; calcium chloride; optionally at least two taste enhancing compounds, and methods of making or using the calcium supplements in the form ...
|
|
WO/2022/071423A1 |
Provided is a pharmaceutical composition that is capable of enhancing the effect of an immune checkpoint inhibitor on a tumor or cancer in a target. The provided pharmaceutical composition, which is to be administered in combination wi...
|
|
WO/2022/071435A1 |
The present invention provides a SARS-CoV-2 protein-derived epitope peptide that has an ability to induce cytotoxic T cells. The present invention also provides a polynucleotide encoding the peptide, an antigen-presenting cell presenting...
|
|
WO/2022/068248A1 |
Provided is the use of a substance for reducing the content or activity of KAT7 in preventing aging and treating hepatic fibrosis. A knocked-down KAT7 gene has a definite effect in delaying aging and treating hepatic fibrosis diseases; a...
|
|
WO/2022/062101A1 |
Provided is the use of a swim-bladder-derived heparin mucopolysaccharide in the preparation of an angiogenesis inhibitor, which use relates to the technical field of medicine. The swim-bladder-derived heparin mucopolysaccharide has the s...
|
|
WO/2022/066845A1 |
The present invention provides methods for co-administration of individual or combinations of monocistronic and / or bicistronic / multicistronic non-viral (including, but not limited to living cells and phages) and / or viral vectors an...
|
|
WO/2022/065354A1 |
One aspect provides a pharmaceutical composition for analgesia. The present invention pertains to a pharmaceutical composition which is for analgesia and contains an α2 adrenergic receptor antagonist as an active ingredient. In one or a...
|
|
WO/2022/063372A1 |
The invention relates to oral analgesic compositions for alleviation of perceived nicotine irritation through inhibition or blocking of nicotine activated receptors or ion channels in the gastrointestinal tract, including the oral cavity...
|
|
WO/2022/065424A1 |
A carcinostatic agent, a carcinogenesis inhibitor and/or a life-prolonging agent each comprising a compound with mTORC1 inhibitory effect, said compound having partial structures (I), (II) and (III), or a pharmacologically acceptable sal...
|
|
WO/2022/063980A1 |
The present invention relates to a composition for use in the prevention or treatment of intestinal microbiota aberration in a Cesarean section (CS) born infant, wherein the use is particularly for one or more of reducing intestinal colo...
|
|
WO/2022/067042A1 |
A cryoprotective composition configured to be applied during cryotreatment of a patient includes at least one biodegradable and/or bioerodible fluid agent and at least one non-toxic cryoprotectant agent. A therapeutically effective amoun...
|
|
WO/2022/065445A1 |
Provided are: an antibody to the spike protein of SARS-CoV-2, the antibody having a specific heavy chain variable region and light chain variable region, or a fragment of said antibody; the antibody or fragment thereof that inhibits bind...
|
|
WO/2022/063963A1 |
The invention relates to a terminally heat-sterilized multi-chamber container for parenteral nutrition, comprising a first chamber containing a macronutrient formulation and a second chamber comprising a vitamin B12 formulation, wherein ...
|
|
WO/2022/067025A1 |
Disclosed herein are compositions and methods for treating multiple sclerosis and alleviating fatigue.
|
|
WO/2022/064839A1 |
The present invention addresses the problem of providing a technique for regulating expression of a gene involved in the production or degradation of collagen, elastin, or hyaluronic acid. This problem is solved by using a composition, f...
|
|
WO/2022/059767A1 |
Provided is an autophagy activator containing, as an active ingredient, a tocopherol phosphate ester or a salt thereof. Also provided is an autophagy activating composition containing the autophagy activator and a pharmaceutically accept...
|
|
WO/2022/058733A1 |
The present invention relates to compounds for stabilising the native tetrameric form of transthyretin and protecting it from proteolytic cleavage; compounds for use in the prevention and treatment of transthyretin amyloidosis; and agent...
|
|
WO/2022/059700A1 |
The present invention provides a triazine compound salt that has an aldosterone synthase inhibitory effect and is useful as a medicine, in particular, an agent for preventing or treating primary aldosteronism and the like, a crystal, and...
|
|
WO/2022/060951A1 |
Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treati...
|
|
WO/2022/058605A1 |
The invention relates to a mouse double minute 2 (MDM2) inhibitor for use in the treatment and/or prevention of a hematologic neoplasm relapse after hematopoietic cell transplantation (HCT) in a patient. In embodiments, the hematologic n...
|
|
WO/2022/059776A1 |
An autophagy activator according to the present invention comprising an inositol derivative, in which a saccharide is bound to inositol, as an active ingredient, and a composition for autophagy activation that comprises the aforesaid aut...
|
|
WO/2022/061234A2 |
The present disclosure provides compositions and methods of using one or more of the metabolites spermidine, palmitoylethanolamide (PEA), oleoylethanolamide (OEA), and 1-methylnicotinamide (1-MNA) to induce an anti-inflammatory, anti-oxi...
|
|
WO/2022/058792A1 |
The disclosure provides carbazole derivatives in combination with Collagenase Clostridium Histolyticum (CCH), and use thereof for the treatment of fat related conditions.
|
|
WO/2022/061094A1 |
Methods and compositions related to solid dosage forms that facilitate the oral delivery of bacteria and/or agents of bacterial origin are provided herein.
|
|
WO/2022/059793A1 |
[Problem] To provide a method for producing a nerve fascicle, the method comprising efficiently elongating an axon of a nerve cell. [Solution] Nerve cells are cultured in the presence of feeder cells including at least one kind of cell s...
|
|
WO/2022/060944A1 |
Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treati...
|
|
WO/2022/060943A1 |
Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treati...
|
|
WO/2022/059794A1 |
An IL-2 mutant protein comprising the amino acid sequence represented by SEQ ID NO: 3 or an amino acid sequence which has at least 95% sequence identity to the amino acid sequence represented by SEQ ID NO: 3 and in which each of the amin...
|
|
WO/2022/059763A1 |
The present invention provides: an autophagy activation agent that contains an ascorbic acid derivative or a salt thereof as the active ingredient; and a composition for autophagy activation, containing the autophagy activation agent and...
|
|
WO/2022/058503A1 |
The invention relates to a cystic fibrosis transmembrane conductance regulator (CFTR) modulator for use in the prevention and/or treatment of diseases involving endothelial and/or epithelial barrier dysfunctions. The disease does not com...
|
|
WO/2022/059779A1 |
The invention of the present application provides an amine derivative having a DYRK-inhibiting activity and represented by formula (1) (see the description with respect to A1, A2, L1, L2, X, Z, R1 and R4 in the formula), or a pharmaceuti...
|
|
WO/2022/059946A1 |
The present invention relates to a pharmaceutical composition for preventing and treating metabolic diseases, and more specifically, for treating nonalcoholic steatohepatitis (NASH) or liver fibrosis through the pharmaceutical compositio...
|
|
WO/2022/059703A1 |
The present invention provides: a cancer therapeutic agent that comprises, as an active ingredient, an apolipoprotein and/or interferon regulatory factor 7 showing enhanced expression in cancer cells administered with Sendai virus envelo...
|
|
WO/2022/058795A1 |
The present disclosure provides methods for the treatment of lipid-related disorders. In some embodiments, the method is a method of reducing the quantity of adipose tissue in need thereof, comprising administering a plurality of injecti...
|
|
WO/2022/059736A1 |
The present disclosure provides a composition effective in preventing, suppressing the progression of, or treating diseases associated with endoplasmic reticulum stress such as defective vesicular transport or disorders such as cell deat...
|
|
WO/2022/058405A2 |
The present invention relates to histone deacetylase inhibitors and to pharmaceutical compositions comprising the same for use for the prevention and/or treatment of autism spectrum disorder, in particular 7Dup and other forms of intelle...
|
|
WO/2022/058271A1 |
The invention provides a composition comprising a therapeutically effective amount of both an uridine and pyruvate compound for use in a method of regulating the proliferation, activity and survival of immune cells to ameliorate and/or p...
|
|
WO/2022/054565A1 |
A cytokine storm inhibitor comprising microparticles derived from a culture supernatant of a dental pulp-derived stem cell, an adipose derived stem cell, a bone marrow-derived stem cell, an umbilical cord-derived stem cell or an immortal...
|
|
WO/2022/054965A1 |
The present invention is concerned with the use of compound in the treatment of dry mouth.
|
|
WO/2022/054927A1 |
Provided is: a composition for autophagy activation which contains a sodium-channel-blocking substance as an active ingredient; a composition for inhibiting the formation of plaques of the causative factor in neurodegenerative disease; a...
|
|
WO/2022/054625A1 |
Provided is a complex containing a pyrrole-imidazole polyamide that recognizes a particular DNA sequence and binds thereto and containing peptide that contains 1-5 arginine residues.
|
|
WO/2022/054748A1 |
Provided is a drug that suppresses the growth of tumor cells by specifically targeting mutant JAK2 and inhibiting hyperactivated JAK2. The following mutant (a) or (b) of erythropoietin. (a) A mutant erythropoietin obtained by introducing...
|
|
WO/2022/054955A1 |
The present invention addresses the problem of providing a lipid composition which enables excellent nucleic acid delivery. Through the present invention, there is provided a lipid composition which includes a lipid represented by formul...
|
|
WO/2022/054778A1 |
[Problem] To provide a sperm motility improving agent that is highly safe and that can effectively improve sperm motility. [Solution] A sperm motility improving agent containing a nicotinamide mononucleotide as an active ingredient.
|
|
WO/2022/053570A1 |
The present invention relates to pyrrolidine compounds for treatment of Xeroderma Pigmentosum (XP), specifically for enhancing DNA repair in a subject suffering from XP.
|
|
WO/2022/053800A1 |
There is described the use of an agent in the manufacture of a therapy for the treatment or alleviation of a senescence-associated disease, disorder or effect, wherein the agent is selected from one or more of A42548, A425619, alpha lipo...
|
|
WO/2022/054798A1 |
Provided is a drug that is useful for photoimmunotherapy. Provided is a complex that contains an antibody molecule, particles having an average particle diameter of 100 nm or less, and a photoreceptive site. In the complex, the particles...
|
